Introduction

Moderate knee osteoarthritis (OA) is a common condition, caused by the gradual wear and tear of cartilage in the knee joint. It often leads to pain, stiffness, and difficulties with movement, affecting many adults, particularly those middle-aged and older. While surgery, such as knee replacement, is often considered for advanced cases, many people want to delay or avoid surgery due to concerns about recovery time, possible complications, and the disruption it can cause to their everyday lives. Arthrosamid has recently emerged as an exciting non-surgical option, offering a “bridge” for those who want to manage their symptoms effectively while staying active.

Understanding Arthrosamid: A Modern Approach to Knee Osteoarthritis

Arthrosamid is an innovative injection designed specifically for moderate knee OA. Unlike traditional injections, such as steroids or hyaluronic acid, Arthrosamid is made from a biocompatible hydrogel that closely mimics the cushioning effect of healthy cartilage. The gel is injected directly into the knee joint using ultrasound to ensure accuracy. This treatment provides long-lasting cushioning and lubrication, helping to reduce pain and improve joint movement. Studies show that “polyacrylamide hydrogel injections… [are] known to be safe and efficacious in knee osteoarthritis patients” (Gao et al., 2025a). When comparing Arthrosamid to other injectables, it’s worth noting that “there was no significant difference in the likelihood of surgical interventions between low-, moderate-, and high-molecular-weight hyaluronic acid users” (Shewale et al., 2017). This highlights the need for new approaches like Arthrosamid that work differently to support knee health.

Who Could Benefit? Finding the Right Candidates

Arthrosamid is best suited for those with moderate knee OA who are not yet ready for surgery or prefer to try non-surgical options first. These individuals usually experience ongoing joint pain and reduced function despite treatments such as physiotherapy, pain relief medication, and lifestyle changes. Research has found that Arthrosamid “provided improvement in knee OA symptoms over 24 months, particularly in older, non-diabetic patients with lower knee OA grades” (Gao et al., 2025a). This suggests that certain patient groups may gain more noticeable benefits, emphasising the importance of a personalised approach.

Delaying Surgery: Arthrosamid as a Valuable Bridge

One of the key advantages of Arthrosamid is its potential to delay the need for surgery. Acting as a “bridge option”, it offers symptom relief and improves joint function, potentially prolonging the life of the natural knee. For example, “49 patients required total knee replacement over two years, with those having more advanced knee OA more likely to have surgery” (Gao et al., 2025a). This underlines how earlier use of Arthrosamid may help some patients postpone surgery. Traditional injectables like hyaluronic acid have been used to delay surgery too. However, a large study observed: “There was no significant difference in the likelihood of surgical interventions between low-, moderate-, and high-molecular-weight hyaluronic acid users after adjusting for confounders” (Shewale et al., 2017). This further supports exploring novel treatments such as Arthrosamid for those looking for more lasting symptom control.

Expert Support: Professor Paul Lee and the London Cartilage Clinic

Choosing the right treatment for knee osteoarthritis benefits from expert advice. Professor Paul Lee, an experienced orthopaedic surgeon and rehabilitation specialist, offers extensive knowledge in cartilage preservation and minimally invasive treatments like Arthrosamid. His roles with the Royal College of Surgeons of Edinburgh demonstrate his commitment to patient care and advancing treatment methods. The London Cartilage Clinic, where Professor Lee practises, provides a welcoming and professional setting with personalised care plans and ongoing support. This ensures patients receive clear guidance to make informed choices about managing their knee OA.

Incorporating Arthrosamid into Your Personal OA Plan

Managing moderate knee OA often requires a combined approach. Arthrosamid can be part of a wider plan alongside physiotherapy, muscle strengthening, weight management, and lifestyle changes designed to protect the joint. It is important to discuss all options with healthcare professionals experienced in knee conditions, as “further studies are warranted to validate efficacy, refine patient selection, and evaluate long-term impact” (Gao et al., 2025a). A personalised plan maximises the chances of maintaining mobility and comfort.

Conclusion

Arthrosamid presents a promising non-surgical option for managing moderate knee osteoarthritis. By cushioning and lubricating the joint, it can help reduce pain, improve movement, and delay the need for surgery, supporting a more active and fulfilling lifestyle. Expert care from specialists like Professor Paul Lee at the London Cartilage Clinic ensures patients receive the best advice and support throughout their treatment journey. Always consult a qualified healthcare professional for personalised medical advice.

References

• Gao, H. C. K., Akhtar, M., Creedon, C., Nar, Ö. O., Verma, T., & Lee, P. Y. F. (2025a). Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study. Journal of Clinical Orthopaedics and Trauma. https://doi.org/10.1016/j.jcot.2025.103136
• Gao, H. C. K., Akhtar, M., Creedon, C., Nar, Ö. O., & Lee, P. Y. (2025b). The impact of patient factors on the minimal clinically important difference of Arthrosamid polyacrylamide hydrogel injection for knee osteoarthritis: A cohort study. Osteoarthritis and Cartilage, [advance online publication]. https://doi.org/10.1016/j.joca.2025.02.648
• Shewale, A. R., Barnes, C. L., Fischbach, L., Ounpraseuth, S., Painter, J. T., & Martin, B. C. (2017). Comparison of low-, moderate-, and high-molecular-weight hyaluronic acid injections in delaying time to knee surgery. The Journal of Arthroplasty, 32(10), 2952-2957.e21. https://doi.org/10.1016/j.arth.2017.04.041